Skip to contentIwicki Mark T — Kala Pharmaceuticals, Inc. insider: 147 transactions · InsiderLensIwicki Mark T
- Director at Inhibikase Therapeutics, Inc. · on record since Feb 25, 2025
- Chief Executive Officer at Inhibikase Therapeutics, Inc. · on record since Feb 25, 2025
- EVP & Chief Commercial Officer at SEPRACOR INC /DE/ · on record since Oct 22, 2007
- Director at Q32 Bio Inc. · on record since Jun 16, 2026
- Director at Aimmune Therapeutics, Inc. · on record since Aug 11, 2015
- Director at Ruthigen, Inc. · on record since Dec 9, 2015
- Director at Kala Pharmaceuticals, Inc. · on record since Jul 21, 2017
- 10% owner at Kala Pharmaceuticals, Inc. · on record since Jul 21, 2017
- Director at Akero Therapeutics, Inc. · on record since Jun 19, 2019
- Director at Merus N.V. · on record since Jan 2, 2020
- Director at Jade Biosciences, Inc. · on record since Jun 29, 2021
- CHIEF EXECUTIVE OFFICER at Kala Pharmaceuticals, Inc. · on record since Jul 21, 2017
- Director at TF FINANCIAL CORP · on record since Sep 14, 2022
Insider trading activity of Iwicki Mark T
- Transactions on record
- 147
- since Oct 22, 2007
- Open-market buys
- 3
- $620K
- Open-market sells
- 14
- $569.6K
- Companies traded
- 10
- last filing Jun 16, 2026
Figures computed from official regulatory filings — methodology.
Companies where Iwicki Mark T has traded
- Q32 Bio Inc.9 tx · Jun 16, 2026
- Inhibikase Therapeutics, Inc.5 tx · Jan 7, 2026
- Merus N.V.20 tx · $7.7M · Dec 12, 2025
- Akero Therapeutics, Inc.15 tx · Dec 9, 2025
- Kala Pharmaceuticals, Inc.44 tx · $569.6K · Oct 24, 2025
- TF FINANCIAL CORP9 tx · Aug 14, 2025
- Jade Biosciences, Inc.6 tx · Jun 7, 2024
- Ruthigen, Inc.10 tx · Feb 1, 2021
- Aimmune Therapeutics, Inc.19 tx · $7.5M · Oct 14, 2020
- SEPRACOR INC /DE/
Track record of Iwicki Mark T
Statistical track record
Free- Open-market buys
- 5
- Last buy
- Apr 3, 2018
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of Iwicki Mark T
Co-insiders of Iwicki Mark T
- Atlas Venture Associates Opportunity I, LLCAkero Therapeutics, Inc. +2
- Atlas Venture Associates Opportunity I, L.P.Akero Therapeutics, Inc. +2
- Atlas Venture Opportunity Fund I, L.P.Akero Therapeutics, Inc. +2
- ORBIMED ADVISORS LLCKala Pharmaceuticals, Inc. +2
- Atlas Venture Associates XI, LLCAkero Therapeutics, Inc. +1
- Atlas Venture Associates XI, L.P.Akero Therapeutics, Inc. +1
- Atlas Venture Fund XI, L.P.
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
10 tx · $12.1M · Oct 22, 2009
Akero Therapeutics, Inc. +1
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jun 16, 2026 | AwardD | 9,810 | 0.00 USD | $0 | SEC |
| Jan 7, 2026 | AwardD | 4,982,706 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -14,414 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -8,631 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -6,120 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -16,604 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -4,983 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -8,500 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -5,650 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -8,844 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | OtherD | -13,193 | 0.00 USD | $0 | SEC |
| Dec 12, 2025 | Other | -73,576 | 97.00 USD | $7.1M | SEC |
| Dec 9, 2025 | OtherD | -26,000 | — | — | SEC |
| Dec 9, 2025 | Other | -9,398 | — | — | SEC |
| Dec 9, 2025 | OtherD | -70,587 | — | — | SEC |
| Dec 9, 2025 | OtherD | -76,227 | — | — | SEC |
| Dec 9, 2025 | OtherD | -13,000 | — | — | SEC |
| Dec 9, 2025 | OtherD | -15,000 | — | — | SEC |
| Dec 9, 2025 | OtherD | -15,000 | — | — | SEC |
| Dec 9, 2025 | OtherD | -13,000 | — | — | SEC |
| Dec 9, 2025 | OtherD | -11,493 | — | — | SEC |
| Oct 27, 2025 | AwardD | 53,521 | 0.00 USD | $0 | SEC |
| Oct 24, 2025 | Sell | -154,894 | 0.81 USD | $125.5K | SEC |
| Aug 14, 2025 | Other | -128,631 | — | — | SEC |
| Aug 14, 2025 | OtherD | -83,296 | 0.00 USD | $0 | SEC |